|Bid||78.20 x 800|
|Ask||78.21 x 1100|
|Day's range||77.16 - 78.29|
|52-week range||72.87 - 89.74|
|Beta (5Y monthly)||0.31|
|PE ratio (TTM)||16.74|
|Earnings date||31 Jan 2024 - 05 Feb 2024|
|Forward dividend & yield||3.00 (3.86%)|
|Ex-dividend date||14 Dec 2023|
|1y target est||89.76|
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
FOSTER CITY, Calif., November 30, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it will present new data at San Antonio Breast Cancer Symposium (SABCS) 2023, supporting the use of Trodelvy® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients.
These stocks aren't popular on the market right now, but investors shouldn't let that scare them off.